Replimune Group
World Rank (Jan-05-2024)
12,365
Market Cap (Jan-05-2024)
0.520 Billion USD
World Rank (Jul-30-2023)
7,950
Market Cap (Jul-30-2023)
1.172 Billion USD
World Rank (Dec-25-2022)
7,081
Market Cap (Dec-25-2022)
1.332 Billion USD
World Rank (Jan-07-2022)
8,400
Market Cap (Jan-07-2022)
1.22 Billion USD
Annual Revenue in USD
0 Million USD
Annual Net Income in USD
-118 Million USD
Annual Results for Period Ending
Mar-2022 ending year
Company Profile
Replimune Group is an emerging class of Cancer Therapeutics company that exploits the ability of viruses to selectively replicate in and kill tumors while at the same time inducing a potent, patient specific, anti tumor immune response. The headquarters is in USA.
Facts About Company
Replimune Group Annual Net loss for year ending Mar-2023 was -174 million USD.
Replimune Group Annual Net loss for year ending Mar-2022 was -118 million USD.
As on 2023, Replimune Group has 284 employees.
Company Website